12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

RoActemra regulatory update

The Scottish Medicines Consortium recommended the use of RoActemra tocilizumab from Roche to treat active systemic juvenile idiopathic arthritis (sJIA) in patients ages >=2 years who have responded inadequately to NSAIDs and systemic corticosteroids - its approved...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >